Accuracy of Five On-Site Immunoassay Drugs-of-Abuse Testing Devices

Published: Journal of Analytical Toxicology, Volume 23, Number 2, March/April 1999, pp.119-124.

Accuracy of Five On-Site Immunoassay Drugs-of-Abuse Testing Devices
E. Howard Taylor, Ernest H. Oertli, Jana W. Wolfgang, and Eric Mueller

Many current “on-site” urine drug-testing products claim performance equivalent to laboratory testing. Five commercially available products (PharmScreen™, Roche TestCup®, Accusign™ DOA 2, Status DS™, and American Bio Medica-Rapid Drug Screen) were challenged with quality-control specimens of known drug metabolite concentrations, 25% above and 25% below the SAMHSA cutoffs, and with known positive and negative donor specimens previously analyzed by immunoassay and gas chromatography–mass spectrometry. The results indicate discrepancies between claims and performance for all products, particularly with amphetamines. The implications for employer-based drug testing are discussed.

Reproduction of editorial content of this journal is prohibited without publisher’s permission.

This article is available in its entirety by fax for $40.00 each.
Visa, MasterCard and AMEX accepted.

To order electronically click here
or call: 847-647-2900 ext. 1323
or fax request to: 847-647-1155.

Please indicate JAT volume and issue along with page numbers.